Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation (RESOLVE)
Prosthetic Valve Thrombosis
About this trial
This is an interventional treatment trial for Prosthetic Valve Thrombosis
Eligibility Criteria
Inclusion Criteria:
- Presence of transcatheter or surgical bioprosthetic aortic valve implanted at least 48 hours prior to enrollment
- Age 18 years or older
- Ability to provide informed consent and follow-up with protocol procedures.
Exclusion Criteria:
- Renal insufficiency (creatinine > 1.5 mg/dL)
- Known allergy to iodinated contrast agents
Sites / Locations
- Cedars-Sinai Medical CenterRecruiting
Arms of the Study
Arm 1
Experimental
Pre-existing bioprosthetic aortic valve
Patients with a history of surgical or transcatheter valve replacement with bioprosthetic valves undergo cardiac contrast CT imaging and transthoracic echocardiography to evaluate structural and functional integrity of the aortic valves. Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.